- Home
- SKYE vs SSP Comparison
SKYE vs SSP Comparison
Compare SKYE & SSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- SSP
- Stock Information
- Founded
- SKYE 2012
- SSP 1878
- Country
- SKYE United States
- SSP United States
- Employees
- SKYE N/A
- SSP N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- SSP Broadcasting
- Sector
- SKYE Health Care
- SSP Industrials
- Exchange
- SKYE Nasdaq
- SSP Nasdaq
- Market Cap
- SKYE 172.9M
- SSP 173.3M
- IPO Year
- SKYE N/A
- SSP 1988
- Fundamental
- Price
- SKYE $5.31
- SSP $1.95
- Analyst Decision
- SKYE Strong Buy
- SSP Buy
- Analyst Count
- SKYE 5
- SSP 2
- Target Price
- SKYE $18.40
- SSP $7.75
- AVG Volume (30 Days)
- SKYE 146.6K
- SSP 574.5K
- Earning Date
- SKYE 11-09-2024
- SSP 11-01-2024
- Dividend Yield
- SKYE N/A
- SSP N/A
- EPS Growth
- SKYE N/A
- SSP N/A
- EPS
- SKYE N/A
- SSP N/A
- Revenue
- SKYE N/A
- SSP $2,317,391,000.00
- Revenue This Year
- SKYE N/A
- SSP $8.99
- Revenue Next Year
- SKYE N/A
- SSP N/A
- P/E Ratio
- SKYE N/A
- SSP N/A
- Revenue Growth
- SKYE N/A
- SSP N/A
- 52 Week Low
- SKYE $1.44
- SSP $1.68
- 52 Week High
- SKYE $19.41
- SSP $9.35
- Technical
- Relative Strength Index (RSI)
- SKYE 42.98
- SSP 42.86
- Support Level
- SKYE $5.71
- SSP $1.68
- Resistance Level
- SKYE $7.11
- SSP $2.07
- Average True Range (ATR)
- SKYE 0.58
- SSP 0.13
- MACD
- SKYE -0.05
- SSP 0.05
- Stochastic Oscillator
- SKYE 0.55
- SSP 52.94
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About SSP E.W. Scripps Company (The)
The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.